Astrana Health (NASDAQ:ASTH) Sets New 12-Month Low on Analyst Downgrade

Astrana Health, Inc. (NASDAQ:ASTH)’s stock price hit a new 52-week low during mid-day trading on Monday after Truist Financial lowered their price target on the stock from $59.00 to $50.00. Truist Financial currently has a buy rating on the stock. Astrana Health traded as low as $29.08 and last traded at $29.42, with a volume of 13470 shares changing hands. The stock had previously closed at $29.48.

Other equities analysts also recently issued reports about the stock. BTIG Research lifted their price objective on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. TD Cowen initiated coverage on shares of Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 price target on the stock. KeyCorp began coverage on shares of Astrana Health in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. Macquarie upgraded Astrana Health to a “hold” rating in a research note on Monday, December 16th. Finally, Robert W. Baird upped their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Astrana Health presently has an average rating of “Moderate Buy” and a consensus target price of $63.67.

Hedge Funds Weigh In On Astrana Health

Several institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC purchased a new position in shares of Astrana Health in the third quarter worth about $34,000. Nisa Investment Advisors LLC bought a new position in Astrana Health in the 3rd quarter worth approximately $35,000. KBC Group NV bought a new position in Astrana Health in the 3rd quarter worth approximately $70,000. Quarry LP purchased a new position in Astrana Health in the 3rd quarter valued at approximately $77,000. Finally, Quest Partners LLC bought a new stake in Astrana Health during the 3rd quarter valued at $133,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Trading Up 3.0 %

The firm has a 50-day simple moving average of $39.07 and a 200-day simple moving average of $46.97. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock has a market cap of $1.75 billion, a PE ratio of 23.99, a P/E/G ratio of 1.80 and a beta of 1.20.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period last year, the business earned $0.47 earnings per share. Equities analysts forecast that Astrana Health, Inc. will post 1.16 earnings per share for the current year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.